mTOR inhibitors and autosomal dominant polycystic kidney disease [6]

New England Journal of Medicine

Volumn 364, Issue 3, 2011, Pages 287-

  Braun, William E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EVEROLIMUS; DRUG DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LETTER; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; DRUG ANTAGONISM; FEMALE; KIDNEY; MALE; NOTE; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY;

FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 78751632517     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Klahr S, Breyer JA, Beck GJ, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995;5:2037-47. [Erratum, J Am Soc Nephrol 1995;6:1318.]